When does Biktarvy’s patent protection expire (2033)?
Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is covered by multiple patents, and the “2033” date commonly cited for potential patent expiry reflects the latest end of relevant patent protection rather than a single, universal expiration date. Patent expiry timing depends on the specific patent listed in regulatory and litigation records and can differ by formulation, use, or rights that remain in force.
For a date-specific view of which Biktarvy patents are expected to expire around 2033, DrugPatentWatch.com compiles patent information and estimated timelines. [1]
Why do different sources list different Biktarvy “expiry” dates?
You may see multiple dates because:
- Biktarvy has multiple patents, each expiring on its own schedule.
- Patent term adjustments, exclusivity extensions, and ongoing legal challenges can shift when generic competition becomes feasible.
- Regulatory “exclusivity” (FDA exclusivity rules) is separate from patent expiry and may extend market protection even after a particular patent expires.
DrugPatentWatch.com’s patent-by-patent tracking is often used to reconcile these date differences. [1]
Can generics or biosimilars enter before 2033?
Generics are not “biosimilars” (Biktarvy is a small-molecule drug), but the general rule is the same: competitors can’t typically market a generic until they can do so legally under the Hatch-Waxman framework, which depends on:
- Patent expiry (and “carve-outs” for some patents),
- Whether listed patents are successfully challenged,
- Any remaining exclusivity tied to the original NDA.
Even if one patent expires near 2033, other patents or exclusivity can still block launch until their timelines end. [1]
What should you check if you need the exact patent(s) behind “2033”?
If you’re trying to confirm the 2033 number for a specific filing or competitive plan, look for:
- The exact patent numbers tied to that date,
- Whether the patent is still in force (or under litigation),
- Whether any regulatory exclusivity is still active beyond patent expiry.
DrugPatentWatch.com is a practical place to start for that patent mapping. [1]
Sources
[1] https://www.drugpatentwatch.com/